Post Offer Free
Wuhan Yuancheng Gongchuang Technology Co,ltd
Wuhan Yuancheng Gongchuang Technology Co,ltd

China Purity Polypeptide Prialt Ziconotide Acetate 2mg manufacturer


Gold Index: 167644

You are here: home  > Injectable Steroid Gear  > Purity Polypeptide Prialt Ziconotide Acetate 2mg

Purity Polypeptide Prialt Ziconotide Acetate 2mg 

Qty (Other,ml) Unit Price (160.0~290.0 USD)
100 - 199 160
200 + 290
Payment Terms: T/T,WU,Money Gram;bitcoin 
Place of Origin: Hubei, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: Ziconotide Acetate 1
Production Capacity: 100000L/WEEK
Delivery Date: with 6 working hours
service: resend guarantee
Supply Ability: Mass Stock
Model Number: Ziconotide Acetate
Usage: Bodybuilding; Male enhancem...
Shipping: 3-7 Days / Door-to-Door
Means of Transport: Air
Packing: brand new
package: Special disguised packaging...
Payment Terms: Western Union, MoneyGram, B...
Certification: ISO
Active-Life: 7-9 days
Lead Time: Within 12 Hours After Payme...

Ziconotide Acetate
Peptide is a connect with peptides and amino acids, but each of these peptides can consist of a variety of amino acids

Polypeptide Hormones ZiconotideAcetate for Bodybuilding

Purity Polypeptide Prialt Ziconotide Acetate 2mg

Product Description

                   Lab Supply Pharmaceutical Intermediate Powder Peptide Ziconotide Acetate 107452-89-1


Ziconotide acetate Basic information
Product Name:Ziconotide acetate
Product Categories:Peptide
Mol File:107452-89-1.mol

Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses. The analgesic efficacy of ziconotide likely results from its ability to interrupt pain signaling at the level of the spinal cord. Ziconotide is a peptidic drug and has been approved for the treatment of severe chronic pain in patients only when administered by the intrathecal route. Importantly, prolonged administration of ziconotide does not lead to the development of addiction or tolerance. The current review discusses the various studies that have addressed the in vitro biochemical and electrophysiological actions of ziconotide as well as the numerous pre-clinical studies that were conducted to elucidate its antinociceptive mechanism of action in animals. In addition, this review considers the pivotal Phase 3 (and other) clinical trials that were conducted in support of ziconotide's approval for the treatment of severe chronic pain and tries to offer some insights regarding the future discovery and development of newer analgesic drugs that would act by a similar mechanism to ziconotide but which might offer improved safety, tolerability and ease of use.

Ziconotide's pharmacological effects have been investigated extensively in pre-clinical in vivo and in vitro models. Briefly, intrathecal ziconotide is a powerful antinociceptive drug in several animal models of chronic pain and it appears to have a completely novel mechanism of action that involves potent and selective block of pre-synaptic neuronal N-type calcium channels in the spinal cord. In fact, it is the only selective N-type channel blocker that is currently approved for clinical use. Evidence suggests that ziconotide delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission. Intrathecal ziconotide's clinical efficacy is consistent with the hypothesis that spinal N-type calcium channels are key regulators of nociceptive signaling in humans, although it is fair to say that its precise analgesic mechanism in humans remains unconfirmed at this time.

Ziconotide: pre-clinical in vivo studies

Ziconotide has been described as a potent and long-lasting antinociceptive drug when administered by the intrathecal route. Experimental evidence of ziconotide's antinociceptive properties was first obtained in the early 1990s and since then extensive studies have been conducted to characterize its effects in multiple animal models of pain. It is also important to note that ziconotide can be efficacious under a variety of intrathecal dosing regimens, including single bolus injection and acute or chronic continuous infusion. Despite its potent efficacy, the therapeutic index of spinal ziconotide tends to be low and often its antinociceptive effects in animals are accompanied by motor deficits at higher doses. Although ziconotide does not easily cross the blood brain barrier in normal animals, it may cause hypotension if it enters the systemic circulation (Bowersox et al 1992; Wright et al 2000; Takahara et al 2002). This effect on blood pressure appears to be mediated at least partially by inhibition of sympathetic neurotransmission, probably as a result of N-type calcium channel blockade in sympathetic nerve terminals (Wang et al 1998).

Ziconotide: clinical studies

The development path to regulatory approval of intrathecal ziconotide involved three large randomized, double-blind, placebo-controlled Phase 3 clinical trials that established the safety and analgesic efficacy of this drug in more than 600 patients (see Table 4A). All of the patients in these trials were suffering from severe chronic pain of malignant and/or non-malignant origins (Staats et al 2004; Rauck et al 2006; Wallace et al 2006) and in order for them to be accepted into the trials, it was necessary that their pain was inadequately controlled by other analgesic drugs, including opioids. These clinical trials evaluated the analgesic efficacy of ziconotide under chronic dosing paradigms (up to 3 weeks) in order to determine the potential for this drug to develop tolerance. In addition to these pivotal trials, a smaller placebo-controlled clinical trial demonstrated analgesic efficacy of ziconotide in a post-surgical setting and a number of open-label studies showed that ziconotide can be an effective therapy in the treatment of neuropathic pain.

Future prospects and concluding remarks

Ziconotide represents a great achievement for current pain therapy but despite its potent analgesic efficacy there remains significant opportunity for improvement. The opportunity derives primarily from the peptidic nature of the drug and its requirement for intrathecal administration in order to yield analgesic efficacy with reduced potential for systemic and central nervous system side-effects. Consequently, drug discovery researchers are considering various approaches to identify and develop novel orally active, N-type calcium channel-selective blockers that have the potential to be superior to ziconotide.

Our process:
The quality control process
Thorough market research, understand the price of raw materials and performance.To the procurement source to understand fully, and fully guarantee the quality of the procurement of raw materials.
2) Inspection
Four steps: sampling, sample pretreatment, measuring and data processing.
3) Producing
a)Each operator must do self-inspection of producs and make the corresponding inspection records.
b)Full-time inspectors through check the operator self-inspection, and review and sign in the corresponding record. Full-time inspection is responsible for inspection of finished product, and make the finished product incoming inspection records.
4) Before selling
Test result can be provided before selling.
Third-party detection institution is allowed if you are not satisfied with test results.
Our advantages:
1. Quality:
Our company is a professional production of hormone intermediates for many years, our products have exported to Germany,Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, you can trust us.
And we are the manufactory, so no problem for us to control the quality.
2.Payment method: Western Union,TT.
3.Service: Best service with after-sales service to all clients.
Sample Order :Package will be shipped with 3days after payment. We can send it via UP, EMS, HK Air Post, DHL or othermethod. We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days.

Other Peptide Our Lab Supply:

ProductPurityCAS No.
Abarelix Acetate98%183552-38-7
Alarelin Acetate98%79561-22-1
Angiotensin Acetate98%58-49-1
Angiotensin II98% 68521-88-0
Antide Acetate98%112568-12-4
Argpressin Acetate98%113-79-1
Argreline Acetate98% 616204-22-9
Atosiban Acetate98%90779-69-4
Aviptadil Acetate98%40077-57-4
Bivalirudin Trifluoroacetate98%128270-60-0
Buserelin acetate98%57982-77-1
Carbetocin Acetate98%37025-55-1
Carperitide98% 89213-87-6
Cecropin B98%
Cetrorelix Acetate98%130143-01-0
Cetrorelix Acetate98%130143-01-0
CJC-129598% 863288-34-0
Copper Peptide(GHK-Cu)98%49557-75-7
CRF (human, rat) Acetate98%86784-80-7
CRF (ovine) Trifluoroacetate98%79804-71-0
Deslorelin Acetate98%57773-65-6
Desmopressin Acetate  98%16679-58-6
Dynorphin A (1-13) Acetate  98%72957-38-1
Elcatonin Acetate98%60731-46-6
Eledoisin Acetate98%69-25-0
Endothelin-1 Acetate98%117399-94-7
Enfuvirtide Acetate (T-20)95%159519-65-0
Eptifibatide Acetate98%148031-34-9/188627-80-7
Exenatide Acetate98%141732-76-5
Felypressin Acetate98%56-59-7
Fertirelin Acetate98%38234-21-8
Ganirelix acetate98%123246-29-7
GHRP-2 Acetate98%158861-67-7
GHRP-6 Acetate98%87616-84-0
Glatiramer Acetate99%147245-92-9
GLP-1 (7-37) Acetate98%106612-94-6

Ms. Gina
skype Ms. Gina
Tel: 86-27-88211875
Mobile: 188 7222 0799
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Other products from this supplier

Company Info

Wuhan Yuancheng Gongchuang Technology Co,ltd [China (Mainland)]

Business Type:Manufacturer, Trading Company
City: Wuhan
Province/State: Hubei
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin Follow us on Twitter

Gina:   skype
Service:   skype

You May Like: